Podium to Practice: ESMO® 2025 – GU: TROPION-PanTumor03

Podium to Practice: ESMO® 2025 – GU: TROPION-PanTumor03

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christian Kollmannsberger

Icon Chair Speaker

Speakers

Dr. Sebastien Hotte

Dr. Maria Jiang

Studies / Trials Discussed

3072MO – Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study

Studies/trials discussed:

3072MO – Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study
Tagged